Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

We recently published a list of 15 Recent Activist Investor Campaigns. In this article, we are going to take a look at where ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

It also offers a high dividend yield of about 8%, which could help keep the stock price from falling much further. The BofA analyst notes that the long-term growth outlook is weaker than average due ...

In summary, income-focused investors may find Pfizer stock an attractive option for making a steady income of $100 per month ...

Vantage with Palki Sharma | N18G Pfizer has halted development of its potential weight loss pill after a patient suffered ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

BofA lowered the firm’s price target on Pfizer (PFE) to $26 from $29 and keeps a Neutral rating on the shares. For Q1, the firm’s total revenue ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...